More Bad News For Pozen: Another Delay To Market For Yosprala
This article was originally published in The Pink Sheet Daily
The company received a second “complete response” letter from FDA for Yosprala, its fixed-dose combination of aspirin and omeprazole, due to issues with the undisclosed third-party supplier.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
If the aspirin/omeprazole finally gets approved on its third FDA review, Aralez then will face the challenge of positioning a prescription product against generic, over-the counter versions of both of its main components.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.